Une année 2017 à oublier, les yeux rivés sur 2018
A l'occasion du BioMed Event clôturant l'année 2017, force est de constater que le secteur Biotech/Medtech a nettement sous-performé le CAC Mid & Small. Malgré des résultats cliniques globalement décevants, nous observons un regain d'intérêt pour le secteur en fin d'année. Les opérations de refinancements et l'appétit pour notre secteur outre atlantique confirment une sous-valorisation manifeste en Europe. Ceci s'est notamment traduit par l'acquisition de VEXIM par STRYKER. Les principaux catalyseurs en 2018 resteront les mêmes pour le secteur BIOTECH, c'est-à -dire: (i) un newsflow clinique important et (ii) des accords de partenariat potentiels. Cf. Etude à paraître.Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.